Related Experiment Video

Updated: Jan 16, 2026

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

1.1K

Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential

Shuangshuang Wei1, Ying Fu1, Yuqing Zeng1

  • 1Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital at Central South University, Changsha, Hunan, China.

Pharmacology & Therapeutics
|September 27, 2025
PubMed

Insights

Acute kidney injury (AKI) can lead to chronic kidney disease (CKD) due to incomplete repair. Lipid metabolism disturbances are key drivers in AKI and its progression to CKD, with potential for targeted therapies.

Area of Science:

  • Nephrology
  • Metabolomics
  • Pathophysiology

Background:

  • Acute kidney injury (AKI) is a common condition with high mortality.
  • Incomplete kidney repair post-AKI can lead to chronic kidney disease (CKD).
  • Altered renal lipid profiles are observed in AKI and CKD.

Purpose of the Study:

  • To investigate the role of lipid metabolism disturbances in AKI.
  • To understand how lipid dysregulation contributes to AKI progression to CKD.
  • To explore therapeutic potential of targeting lipid metabolism.

Main Methods:

  • Analysis of renal lipid profiles in AKI and CKD models and patients.
  • Investigating lipid accumulation, peroxidation, and lipotoxicity.
  • Evaluating pharmacological interventions targeting lipid metabolism.

Main Results:

  • Significant alterations in lipid metabolism are evident in AKI and CKD.
  • Lipid dysregulation is linked to AKI initiation and progression to CKD.
  • Targeting lipid metabolism shows therapeutic promise in AKI-CKD models.

Conclusions:

  • Lipid metabolism plays a critical role in AKI pathogenesis and CKD development.
  • Understanding lipid changes is crucial for AKI and CKD management.
  • Pharmacological targeting of lipid pathways offers a potential therapeutic strategy.
Keywords:
Acute kidney injuryKidney repairLipid metabolismLipotoxicity

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.1K
Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.7K

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
923
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
555
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169